The productivity internet will sell you anything.

Nootropic stacks. Neurofeedback devices. Omega-3 regimens. Color-coded planners with specific “brain flow” layouts. And every one of them has a Reddit thread, an influencer, and a testimonial stack saying it changed someone’s life. I’ve bought into several of them.

A landmark study published February 10, 2026 just put the whole thing in evidence order. Researchers led by Professor Samuele Cortese analyzed over 200 meta-analyses covering 31 different ADHD interventions, and published a free interactive website so you can look up exactly how strong (or weak) the evidence is for anything you’re currently spending money on.

Here’s what the research actually says, and what it means for how you spend your time and money in 2026.

TL;DR

Intervention	Evidence Strength	Best For
Stimulant medications	Strong (short-term)	Children and adults; biggest effect sizes
Atomoxetine	Moderate-high	Adults; non-stimulant option
CBT	Strong for adults	Executive function, coping skills
Mindfulness	Limited (promising long-term)	Adults; not children
Exercise	Limited	Adjunct, not standalone
Omega-3 supplements	Low/conflicted	Core symptoms: likely not worth it
Neurofeedback	Low certainty	Not recommended as primary strategy

The gap everyone ignores: Almost all strong evidence covers short-term effects only—typically weeks to months of clinical trial data. Long-term evidence for any intervention is weak or nonexistent.

What this means for you: Medications and CBT aren’t just “popular.” They have the most rigorous evidence behind them. Most supplements and alternative tools have little or none.

Why This Study Is Different From the Others

Every few months, a study gets shared around ADHD communities as proof that [X intervention] works. Usually it’s a single small trial with specific conditions that don’t generalize well.

This study is categorically different. The research team—based at the University of Southampton and Université Paris Nanterre—didn’t run a new experiment. They synthesized 221 separate meta-analyses, each of which was itself a synthesis of multiple clinical trials. Then they re-ran the statistics with a standardized pipeline so results across interventions could be compared directly.

The result covers 31 different interventions across 24 clinical outcomes. It’s not one team’s findings. It’s a structured review of almost everything that’s been studied.

And they didn’t bury it in a journal. The researchers built a free, publicly accessible interactive database at ebiadhd-database.org where anyone can look up any intervention, see its evidence rating, and understand what that rating means in plain language.

What Actually Has Evidence Behind It

Medications: Strong Evidence, Real Limitations

For children and adolescents, five medications showed medium-to-large effect sizes with moderate-to-high certainty evidence: alpha-2 agonists, amphetamines, atomoxetine, methylphenidate, and viloxazine.

For adults, the list is shorter but still solid: atomoxetine, methylphenidate, and amphetamines (in high-quality trials) all demonstrated at least moderate-certainty evidence with medium effect sizes.

The limitation the study explicitly flags: this evidence is almost entirely short-term. Most clinical trials run for weeks or a few months. The fact that methylphenidate works over a 12-week trial tells you less than you’d want to know about what happens if you take it for 5 years. That long-term data gap is real, and the study calls it out as a major gap in the research.

This doesn’t mean medication doesn’t work long-term. It means we don’t have the same rigorous evidence that we do for short-term use. If you’re making long-term medication decisions, this is a genuine conversation to have with your prescriber. Not a reason to panic.

If you’re currently dealing with medication availability issues, the ADHD medication shortage productivity guide covers what to do when your prescription isn’t accessible.

CBT: The Strongest Non-Medication Option for Adults

Cognitive Behavioral Therapy came out with strong evidence for adults, comparable to medication in the rigor of the research behind it.

CBT for ADHD isn’t the same as CBT for depression. The ADHD-specific version is built around task initiation and organization: why it breaks down, what to do when it does. It also addresses time management, avoidance patterns, and the emotional aftermath of chronic ADHD challenges (the shame, the frustration, the relationship strain).

For a productivity context, CBT addresses the executive function layer directly. Not “think positively about your to-do list.” More like: figure out why initiation keeps failing, then build external structures around the failure point. I think of it as the difference between having a better map vs. hoping to magically care more about the territory.

The evidence for CBT in children is weaker—not because it doesn’t help, but because the research there uses harder-to-assess outcomes and smaller samples with higher bias risk.

Mindfulness: Promising at Long-Term, Weak Evidence Overall

Here’s the nuanced one. Mindfulness appeared to have large effects at extended follow-up, making it the only intervention that showed this pattern. That’s interesting enough to notice.

But the evidence quality was low: small studies, higher bias risk, inconsistent measurement. “Large effect size with low-certainty evidence” doesn’t mean it works. It means the few studies that exist showed big numbers, but there aren’t enough rigorous studies to trust those numbers yet.

If mindfulness is already part of your toolkit and you find it genuinely useful, keep it. But don’t replace structured approaches or medication with mindfulness on the basis that “studies show it works.” The evidence doesn’t support that claim at anywhere near the same level.

Exercise: Useful Adjunct, Not a Treatment

Exercise showed up in the data with some positive effects, but again: low-certainty evidence, limited study quality. There are good mechanistic reasons to think exercise helps ADHD (dopamine, norepinephrine, executive function support), and there’s reasonable evidence for short-term effects on attention.

The distinction matters for how you think about it in your day. Exercise as one component of a system? Legitimate and worth building in. Exercise as a replacement for other evidence-based approaches? Not supported by the data.

What the Evidence Doesn’t Support

This is the part most ADHD productivity content skips.

Omega-3 supplementation has been heavily marketed to ADHD communities for years. The umbrella review found low-certainty, conflicting evidence. Some studies show modest effects on specific symptom clusters; others show nothing.

The current evidence base doesn’t support omega-3 as a reliable intervention for core ADHD symptoms. If you’re spending $50/month on fish oil specifically for ADHD, the research doesn’t back that investment.

Neurofeedback has been a persistent topic in ADHD discussions for over a decade. The Cortese review found low-certainty evidence: small studies, inconsistent results. When comparing against active controls (rather than no treatment), the effects largely disappear.

Multiple reviews have reached the same conclusion. Neurofeedback may help some people; it’s not a validated ADHD treatment with replicable evidence.

Acupuncture showed up with large apparent effect sizes in children, but the certainty was low and the bias risk in those studies was high. Not enough to recommend.

The study’s framing here is important: these aren’t interventions that “definitely don’t work.” They’re interventions where we don’t have good enough evidence to say they work. That’s a different claim, but it’s one that should inform where you put your money and time.

What This Means for Your Productivity Stack

Most ADHD productivity content focuses on apps, systems, and frameworks. This study doesn’t address apps directly. It’s about clinical interventions. But the findings translate directly to how you think about your broader support stack.

If you’re not in CBT and you’ve hit a ceiling with productivity tools alone, the evidence suggests CBT is the most well-supported next step for ADHD adults. Not journaling apps or mindfulness courses. Actual CBT with an ADHD-informed therapist. The distinction matters because CBT for ADHD uses a specific structure that general therapy doesn’t always provide.

If you’re evaluating supplements or alternative tools, use ebiadhd-database.org as your first filter. Look it up before you buy. If the evidence is weak or absent, that should weigh in your decision.

Productivity tools and apps work differently than clinical interventions. A great app can genuinely reduce friction, compensate for working memory gaps, and make your whole system more reliable. That’s real.

But apps accommodate ADHD; they don’t treat it. The clinical interventions in this study target the underlying neurological function. Both matter. They’re not competing.

For building the tool layer of your stack, the best working memory tools guide and best AI ADHD coaching apps are worth reading alongside this evidence context.

The Featured-Snippet Version: What Works for ADHD Adults in 2026

Strongest evidence (moderate-to-high certainty):

• Stimulant medications (methylphenidate, amphetamines)
• Atomoxetine (non-stimulant)
• CBT for adults

Promising but limited evidence:

• Mindfulness (especially longer-term)
• Exercise (adjunct use)

Weak or insufficient evidence:

• Omega-3 supplementation for core symptoms
• Neurofeedback
• Most supplements marketed for ADHD focus

Major gap the study flags: Almost no rigorous long-term evidence exists for any intervention.

One Thing to Do With This Information

The interactive database at ebiadhd-database.org is genuinely worth bookmarking. It’s designed for regular people, not just clinicians. You can search any intervention, see the evidence rating, and understand what the certainty level means without having to interpret statistical jargon.

Action (10 minutes): Bookmark the site right now. Pull up one supplement or tool you’re currently using and look it up. Not to guilt yourself. Just to know what you’re working with.

If your current stack includes tools you’re not sure about, this is your framework for evaluating them honestly. The answer isn’t always “throw it out if evidence is weak.” Sometimes a lower-evidence intervention works for your specific brain and situation. But knowing the evidence level helps you hold it with the right level of confidence.

The ADHD dopamine menu system and body doubling apps are examples of tool-layer approaches that don’t require clinical evidence to be practically useful. They’re working with real neurological dynamics even if they haven’t been through the same trials.

The evidence from this study doesn’t make your system wrong. It just gives you a more accurate map of what’s doing what.

---

The study, “Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making,” was published in The BMJ in 2025, with the public interactive platform launched February 10, 2026. Full details at ebiadhd-database.org.